Table 1.
Baseline characteristics of patients according to re-TUR status
| Variable | No Re-TUR (%) | Re-TUR (%) | Re-TUR Unknown (%) | All patients (%) |
|---|---|---|---|---|
|
| ||||
| N | 1342 | 935 | 174 | 2451 |
|
| ||||
| Age | ||||
| < 70 yrs | 726 (52.4) | 549 (39.6) | 110 (7.9) | 1385 (56.5) |
| ≥ 70 yrs | 616 (57.8) | 386 (36.2) | 64 (6.0) | 1066 (43.5) |
| Median (yrs) | 69 | 67 | 67 | 68 |
| Interquartile range (yrs) | 61 – 75 | 59 – 74 | 60 – 72 | 60 – 74 |
|
| ||||
| Sex | ||||
| Male | 1112 (55.3) | 756 (37.6) | 144 (7.2) | 2012 (82.1) |
| Female | 230 (52.4) | 179 (40.8) | 30 (6.8) | 439 (17.9) |
|
| ||||
| Tumor status | ||||
| Primary T1G3 | 1175 (53.9) | 848 (38.9) | 156 (7.2) | 2179 (88.9) |
| Recurrent after non T1G3 | 167 (61.4) | 87 (32.0) | 18 (6.6) | 272 (11.1) |
|
| ||||
| Previous intravesical chemotherapy | ||||
| No | 1261 (54.4) | 895 (38.6) | 164 (7.1) | 2320 (94.7) |
| Yes | 81 (61.8) | 40 (30.5) | 10 (7.6) | 131 (5.3) |
|
| ||||
| Muscle in primary TUR specimen | ||||
| No | 130 (31.3) | 276 (66.4) | 10 (2.4) | 416 (17.0) |
| Yes | 1092 (61.8) | 624 (35.3) | 52 (2.9) | 1768 (72.1) |
| Missing/Unknown | 120 (72.3) | 35 (21.1) | 112 (6.6) | 267 (10.9) |
|
| ||||
| Tumor grade | ||||
| WHO 1973 grade 3 | 1090 (64.0) | 442 (26.0) | 171 (10.0) | 1703 (69.5) |
| WHO 2004 high grade | 978 (54.9) | 799 (44.9) | 3 (0.2) | 1780 (72.6) |
| Grade 3 and/or high grade | 1342 (54.8) | 935 (38.1) | 174 (7.1) | 2451 (100) |
|
| ||||
| Tumor focality | ||||
| Solitary | 618 (64.1) | 225 (23.3) | 121 (12.6) | 964 (39.3) |
| Multiple | 631 (46.2) | 687 (50.3) | 47 (3.4) | 1365 (55.7) |
| Missing/Unknown | 93 (76.2) | 23 (18.9) | 6 (4.9) | 122 (5.0) |
|
| ||||
| Largest tumor diameter | ||||
| < 3 cm | 806 (70.9) | 257 (22.6) | 74 (6.5) | 1137 (46.4) |
| ≥ 3 cm | 326 (58.2) | 191 (34.1) | 43 (7.7) | 560 (22.8) |
| Missing/Unknown | 210 (27.9) | 487 (64.6) | 57 (7.6) | 754 (30.8) |
|
| ||||
| Concomitant CIS | ||||
| No | 1019 (55.0) | 694 (37.5) | 139 (7.5) | 1852 (75.6) |
| Yes | 323 (53.9) | 241 (40.2) | 35 (5.8) | 599 (24.4) |
|
| ||||
| Invasion of prostatic urethra | ||||
| No | 936 (70.0) | 401 (30.0) | 0 | 1337 (54.6) |
| Yes, without stromal invasion | 26 (59.1) | 18 (40.9) | 0 | 44 (1.8) |
| Yes, with stromal invasion | 2 (40.0) | 3 (60.0) | 0 | 5 (0.2) |
| Missing/Unknown | 378 (35.5) | 513 (48.2) | 174 (16.3) | 1065 (43.4) |
|
| ||||
| Pathology at restaging TUR* | ||||
| No residual tumor | NA | 267 (28.6) | NA | 267 (28.6) |
| Ta | NA | 378 (40.4) | NA | 378 (40.4) |
| T1 | NA | 289 (30.9) | NA | 289 (30.9) |
| CIS | NA | NA** | NA | NA** |
| Missing/Unknown | NA | 1 (0.1) | NA | 1 (0.1) |
|
| ||||
| Maintenance BCG | ||||
| No | 753 (49.7) | 624 (41.2) | 138 (9.1) | 1515 (61.8) |
| Yes | 589 (62.9) | 311 (33.2) | 36 (3.9) | 936 (38.2) |
**
Separate information on CIS at re-TUR was not available.